Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).

Abstract

The article "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)", written by M.J.G.T. Vehreschild et al., was originally published at Springerlink on 11 August 2018 without open access.

• Authors: Maria J G T Vehreschild, Surabhi Taori, Simon D Goldenberg, Florian Thalhammer, Emilio Bouza, Joop van Oene, Graham Wetherill, Areti Georgopali
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 38 Issue 1 Pg. 199 (01 2019) ISSN: 1435-4373 [Electronic] Germany
• PMID: 30406879 (Publication Type: Journal Article, Published Erratum)